Irinotecan Vista for infusions 20 mg/ml. 15 ml/300 mg. vial

$388.00

Manufacturer: Italy

Purpose: Inhibits topoisomerase I for treating colorectal cancer.

SKU: MED58961 Category:

Description

Irinotecan Vista for Infusions 20 mg/ml. 15 ml/300 mg Vial

Ingredients

Active ingredient: Irinotecan hydrochloride trihydrate. Inactive ingredients: Mannitol, lactic acid, and water for injections.

Dosage

Dosage: The recommended dose of Irinotecan Vista for infusion is determined by the patient’s body surface area and the specific treatment regimen. It is administered intravenously over a specific period as directed by a healthcare professional.

Indications

Indications: Irinotecan Vista is indicated for the treatment of colorectal cancer and small cell lung cancer. It is used in combination with other chemotherapy agents for these indications.

Contraindications

Contraindications: Irinotecan Vista is contraindicated in patients with a known hypersensitivity to irinotecan or any of the inactive ingredients. It should not be used in patients with severe bone marrow suppression.

Directions

Administration: Irinotecan Vista should only be administered by healthcare professionals experienced in the use of chemotherapy agents. It is given as an intravenous infusion, and the infusion rate should be carefully controlled to minimize the risk of adverse reactions.

Scientific Evidence

Irinotecan is a topoisomerase I inhibitor that exerts its antitumor effects by interfering with DNA replication and transcription. Studies have shown its efficacy in treating various cancers, particularly colorectal and lung cancers.

Clinical trials have demonstrated the benefits of Irinotecan Vista in improving progression-free survival and overall survival rates in patients with advanced colorectal cancer. Its use in combination regimens has shown promising results in increasing treatment response rates.

Additional Information

It is essential for healthcare providers to closely monitor patients receiving Irinotecan Vista for any signs of adverse reactions, such as neutropenia, diarrhea, and nausea. Dose adjustments may be necessary based on individual patient factors to optimize treatment outcomes.

Patient education regarding potential side effects and the importance of adherence to the prescribed treatment regimen is crucial for ensuring the best possible therapeutic results with Irinotecan Vista.